Author:
Ye Cai Guo,Liu Liping,Chen George G,Tang Xiao Lin,He Zhiwei,He Ming-Liang,Lai Paul BS
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference35 articles.
1. To AK, Chen GG, Chan UP, Ye C, Yun JP, Ho RL, et al. ZBP-89 enhances Bak expression and causes apoptosis in hepatocellular carcinoma cells. Biochim Biophys Acta. 2011;1813:222–30.
2. Ye CG, Chen GG, Ho RL, Merchant JL, He ML, Lai PB. Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma. Bba-Mol Cell Res. 2013;1833:2970–9.
3. Lopez-Soto A, Folgueras AR, Seto E, Gonzalez S. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene. 2009;28:2370–82.
4. Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell. 2011;43:811–22.
5. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012;56:1343–50.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献